Skip to main content
. 2022 Aug 24;26(1):26–43. doi: 10.1007/s10120-022-01332-7

Fig. 1.

Fig. 1

The design of this study. Schematic illustration of process of samples based on different analysis assays, which were contained PCR, TDM of IM and sensitive metabolites screening of IM treatment on GISTs patients. And the cell validation of IM-insensitivity was highly related with SPK1/S1P pathway. Blocking of SPK1/S1P pathway would confer the sensitivity of IM in GISTs therapy